CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

THERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.